Analysts Set Shire PLC (SHPG) Price Target at $202.00
Shire PLC (NASDAQ:SHPG) has received an average rating of “Buy” from the fourteen research firms that are covering the firm, Marketbeat reports. Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $202.00.
A number of brokerages have commented on SHPG. BidaskClub upgraded Shire from a “hold” rating to a “buy” rating in a research report on Tuesday, December 25th. Cantor Fitzgerald set a $222.00 price target on Shire and gave the stock a “buy” rating in a research report on Thursday, December 20th. William Blair cut Shire from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 20th. SunTrust Banks cut Shire from a “buy” rating to a “hold” rating in a research report on Tuesday, December 11th. Finally, ValuEngine upgraded Shire from a “sell” rating to a “hold” rating in a research report on Thursday, December 6th.
Shares of NASDAQ:SHPG remained flat at $$179.20 during midday trading on Friday. The stock has a market cap of $54.71 billion, a price-to-earnings ratio of 11.83, a PEG ratio of 1.54 and a beta of 0.87. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 0.36. Shire has a fifty-two week low of $123.73 and a fifty-two week high of $182.47.
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Further Reading: How Do Mutual Funds Work?
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.